Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s

Scandinavian Journal of Rheumatology

Volumn 44, Issue 3, 2015, Pages 173-181

  Uutela, T ^a,b   Kautiainen, H ^c   Jarvenpaa S ^d   Salomaa, S ^a   Hakala, M ^e   Hakkinen A ^f  

^a LAPLAND CENTRAL HOSPITAL   (Finland)

^b MEDICAL RESEARCH CENTER OULU   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Medcare Foundation   (Finland)

^e PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF JYVÄSKYLÄ   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PODOPHYLLOTOXIN; PREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CROSS-SECTIONAL STUDY; FEMALE; FUNCTIONAL STATUS; GENERAL HEALTH STATUS ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTTINGHAM HEALTH PROFILE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; WORK CAPACITY; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; DIABETES MELLITUS; EMPLOYMENT; FINLAND; HEALTH STATUS; HYPERLIPIDEMIAS; HYPERTENSION; MIDDLE AGED; NEOPLASMS; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASES; TRENDS;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; EMPLOYMENT; FEMALE; FINLAND; HEALTH STATUS; HUMANS; HYDROXYCHLOROQUINE; HYPERLIPIDEMIAS; HYPERTENSION; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; RESPIRATORY TRACT DISEASES; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929329670     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.957240     Document Type: Article

References (45)

1. Scott DL, Smith C, Kingsley G. What are the consequences of early rheumatoid arthritis for the individual. Best Pract Res Clin Rheumatol 2005;19:117-36.
2. Verstappen SMM, Symmons PM. What is the outcome of RA and can we predict it? Best Pract Res Clin Rheumatol 2011;25:485-96.
3. Sokka T. Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol 2010;28(Suppl 61);13-20.
4. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage with early rheumatoid arthritis by initial aggressive treatment with diseasemodifying anti-rheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum 2004;50:2072-81.
5. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications. Results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46;1164-70.
6. Jurgens MS, Jacobs JWG, Bijlsma JWJ. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol 2011:25;523-33.
7. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis. Published online: 25 October 2013. doi: 10.1136/annrheumdis- 2013-204573.
8. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
9. Rantalaiho VM, Kautiainen H, Järvenpää S, Virta L, Pohjolainen T, Korpela M, et al. Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8. Ann Rheum Dis 2013;72:672-8.
10. Strand V, Singh J. Improved health-related quality of life with effective disease modifying anti-rheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13(Suppl 9):237-50.
11. Kievit W, Fransen J, de Waal Malefijt MC, den Broeder AA, van Reil PL. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford) 2013;52:1500-8.
12. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-19.
13. Ziegler S, Huscher D, Karberg K, Krause A, Wassenberg S, Zink A. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centre. Ann Rheum Dis 2010;69:1803-8.
14. Krishnan E, Lingala B, Bruce B, Fries J. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis 2012;71:213-18.
15. Baldini C, Sedie AD, Bombardieri S. From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials? Clin Exp Rheumatol 2005;23:893-904.
16. Tiippana-Kinnunen T, Kautianen H, Paimela L, Leirisalo-Repo M. Comorbidities in Finnish patients with rheumatoid arthritis: 15-year follow-up. Scand J Rheumatol 2013;42:451-6.
17. Radner H, Smolen JS, Aletaha D. Comorbidities affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:381-8.
18. Jylhä M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Soc Sci Med 2009;69:307-16.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
21. Fransen J, Creemers CW, Van Riel LCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary criteria. Rheumatology (Oxford) 2004;43:1252-5.
22. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;17:481-91.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
24. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003;56:221-9.
25. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
26. Hunt SM, McEwen J, McKenna SP. Measuring health status. London: Croom Helm, 1986.
27. Hakala M, Nieminen P, Manelius J. Joint impairment is strongly correlated with disability measured by self-reported questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population based series. J Rheumatol 1994;21:64-9.
28. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcomes in arthritis. Arthritis Rheum 1980;23:137-45.
29. Lundberg O, Manderbacka K. Assessing reliability of a measure of self-rated health. Scand J Soc Med 1996;24:218-24.
30. Sany J, Bourgeois P, Saraux A, Durieux S, Lafuma A, Daurès JP, et al. Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital rheumatologists. Ann Rheum Dis 2004;63:1235-40.
31. Sokka T, Krishnan E, Häkkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003;48:59-63.
32. Schmajuk G, Solomon DH, Yazdany J. Patterns of diseasemodifying drug use in rheumatoid arthritis patients after 2002: a systematic review. Arthritis Care Res (Hoboken) 2013;65:1927-35.
33. Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, et al. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clin Exp Rheumatol 2013;31:409-14.
34. Rantalaiho V, Kautiainen H, Virta L, Korpela M, Möttönen T, Puolakka K. Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. Scand J Rheumatol 2011;40:16-21.
35. Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, et al. The good initial response to therapy with a combination of traditional disease-modifying anti-rheumatic drugs is sustained over time. The eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy Trial. Arthritis Rheum 2009;60:1222-31.
36. Jämsen E, Virta LJ, Hakala M, Kauppi MJ, Malmivaara A, Lehto MU. The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of antirheumatic therapy. Acta Orthop 2013:84:331-7.
37. Young A, Wilkinson P, Talamo J, Dixey N, Cox P, Davies J, et al. Socioeconomic deprivation and rheumatoid disease: what lessons for the health service? ERAS Study Group. Early Rheumatoid Arthritis Study. Ann Rheum Dis 2000;59:794-9.
38. Aromaa A, Huttunen J, Koskinen S, Teperi J, editors. Health in Finland [in Finnish]. Suomalaisten terveys Duodecim: Helsinki, 2005;444-65.
39. Lacaille D, Sheps S, Spinelli JJ, Chalmers A, Esdaile JM. Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Rheum 2004;51:843-52.
40. Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C, et al. Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? Ann Rheum Dis 2012;71:1942-9.
41. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacological interventions (RAPP-PI) outcomes. Arthritis Care Res (Hoboken) 2010;62:647-56.
42. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The link between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:122-32.
43. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41;1072-82.
44. Hakala M, Hannonen P, Helve T, Korpela M, Mattila K, Möttönen T, et al. Rheumatoid arthritis (updated Current Care guideline) [in Finnish (abstract in English)]. Duodecim 2009;125:2131-2.
45. Björk M, Trupin L, Thyberg I, Katz P, Yelin E. Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up. Scand J Rheumatol 2011;40:428-43.